MJMohamed Bellah Jalloh

Mohamed Bellah Jalloh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mohamed Bellah Jalloh has a total of 186 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Hypertension care cascade and cardiometabolic risk-factor burden among adults screened in Sierra Leone: May Measurement Month 2023

    by Foray Mohamed Foray, Christine E.E. Williams, Oluwanfunmike G. Jegede, Monalisa M.J. Faulkner, Fatima Jalloh, Theresa R. Koroma, Henry Sankoh, Mohamed B. Jalloh

  • Open Access

    Global inequalities in cardiometabolic care and achievable cardiovascular risk reduction by wealth, region, and sex: a pooled analysis of individual participant data from 76 countries

    by Bamba Gaye, Gurbinder Singh, Elisabeth L P Sattler, Moustafa I Morsy, Ahmed Abdelnoor, Liliana Aguayo, Jennifer Carter, Robert J Clarke, Sokhna Dieng, Hassim Bachir Diop, et al.

  • Open Access

    Trends of age-standardised hypertension prevalence, treatment, and control among adults aged 30–79 years in Africa from 1990 to 2019

    by Ngone D. Gaye, Mohamed B. Jalloh, Tiffany L. Gary-Webb, Ishta Madan, Johann Edjimbi, Mame Madjiguene Ka, Demeke Mekonnen, Papa M.D. Fall, Tacko Niang, Hassim B. Diop, et al.


  • Open Access

    Global Inequalities in Cardiometabolic Care and Achievable Cardiovascular Risk Reduction by Wealth, Region, and Sex: A Pooled Analysis of Individual Participant Data From 76 Countries

    by Gaye Bamba, Gurbinder Singh, Elisabeth Sattler, Moustafa I. Morsy, Ahmed T. AbdelNoor, Liliana Aguayo, Jennifer Carter, Robert Clarke, Sokhna Dieng, Hassim B. Diop, et al.

    Background: Wealth-related inequalities affect cardiometabolic health worldwide, but their implications for cardiometabolic care and potentially preventable cardiovascular disease remain poorly understood. Methods: We analysed harmonised, nationally representative health examination surveys from 76 countries (109 surveys) in five WHO regions. Adults aged 18 years or older with data on age, sex, wealth, and at least one cardiometabolic outcome were eligible. Disease status was defined from measured biomarkers, self-reported diagnosis, or current medication; awareness and treatment were based on self-reported information, and control on measured biomarkers. Each indicator was expressed as the proportion of all individuals with the corresponding condition. Inequality was quantified by the wealthiest–poorest quintile difference and the slope index of inequality (SII). Predicted 10-year cardiovascular risk was estimated with Globorisk, and trial-derived relative risk reductions applied to estimate achievable absolute risk reduction. Findings: Among 315 403 participants (median age 40 years [IQR 30–52]; 185 209 [58·7%] women), inequalities widened progressively across the care cascade in all regions and were most pronounced for disease control. Pooled across regions, the SII for control increased from hypertension (0·04, 95% CI 0·02–0·06) to diabetes (0·05, 0·01–0·09) and hypercholesterolaemia (0·07, 0·04–0·09). However, regional patterns varied substantially. In the Americas, disease control consistently favoured wealthier individuals (hypertension SII 0·09, 0·01–0·18), whereas in Africa coverage was uniformly low, and the largest inequality was pro-poor, particularly for hypercholesterolaemia treatment (SII −0·38, −0·50 to −0·26). Baseline cardiovascular risk was higher among the poorest (13·6% vs 12·2%), but achievable risk reduction aligned more closely with baseline risk than with treatment coverage being greatest in Europe (3·9%) and lowest in Africa (2·5%). Across all regions, achievable risk reduction was greater in men than in women (EURO 4·6% vs 3·5%), reflecting sex-specific risk functions rather than differences in access to care. Interpretation: Populations with the largest treatment gaps are not necessarily those in which expanding treatment would prevent the greatest burden of cardiovascular disease. In settings where coverage is uniformly low, expanding the supply of care matters more than redistributing access to it. Moreover, because socioeconomic inequalities widen after diagnosis, screening alone is unlikely to reduce disparities unless accompanied by sustained access to treatment. Policy should therefore define whether its primary objective is to maximise equity or overall population health gains.

  • Open Access

    Rising burden of Alzheimer’s disease and other dementias in Sierra Leone, 1990–2023: analysis of Global Burden of Disease 2023 estimates

    by Mohamed B Jalloh, Gibrilla Fadlu Deen, Omar Bah, Ishmaela Bah, Abdul Aziz Suma, Onome T Abiri, Melvina C Thompson, Edries Tejan, Fatima Jalloh, Foray Mohamed Foray, et al.

    Background: Dementia is an increasing cause of disability and mortality worldwide. Primary dementia surveillance data remain limited in many low-income settings, including Sierra Leone. Objective: To describe trends in Burden of Disease (GBD) 2023 modelled estimates for Alzheimer’s disease and other dementias in Sierra Leone from 1990 to 2023, and to decompose the change in estimated deaths into demographic and age-specific mortality components. Methods: We conducted a secondary analysis of GBD 2023 estimates for the cause category ‘Alzheimer’s disease and other dementias’ in Sierra Leone. We analysed estimated counts and age-standardised rates for prevalence, deaths, years of life lost, years lived with disability and disability-adjusted life years (DALYs) stratified by age and sex. Temporal trends were described with log-linear regression to estimate annual per cent change, and a three-component decomposition attributed changes in deaths to population growth, ageing and age-specific mortality. Results: GCD 2023 estimated that dementia deaths in Sierra Leone increased from 188 in 1990 to 474 in 2023, an absolute increase of 286 estimated deaths (152% relative increase). Estimated DALYs increased from 3703 to 7440. The modelled age-standardised death rate rose 26.8% (16.3 to 20.7 per 100 000) and the age-standardised DALY rate 13.4% (293.7 to 333.2 per 100 000). Estimated prevalent cases increased from 5647 to 8887, while the modelled age-standardised prevalence rate declined from 430.7 to 404.0 per 100 000 population. The log-linear annual percentage change was +1.02% for age-standardised death rates, +0.60% for DALY rates and −0.18% for prevalence rates. Decomposition attributed 62% of the increase in estimated deaths to changes in age-specific mortality, 30% to population growth and 8% to population ageing. Conclusions: GBD 2023 estimates show a rising absolute burden of dementia in Sierra Leone, against a background of limited local surveillance and mortality ascertainment.

  • Open Access

    Trends in the burden of sickle cell disorders in Sierra Leone, 1990–2023: An analysis of Global Burden of Disease Study 2023 estimates

    by Monalisa M. J. Faulkner, Fatima Jalloh, Foray Mohamed Foray, Sahr L. Gborie, Mohamed B. Jalloh

    Background: Sickle cell disease is a major cause of childhood mortality in sub-Saharan Africa, yet country-specific burden estimates for high-prevalence settings in West Africa remain limited. Objective: To describe Global Burden of Disease (GBD) 2023 modeled estimates of sickle cell disorders burden in Sierra Leone from 1990 through 2023, including temporal trends, age and sex patterns, and demographic contributors to mortality change. Methods: We analyzed GBD 2023 modeled estimates for sickle cell disorders in Sierra Leone, including prevalence, deaths, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs) as absolute counts and age-standardized rates. Temporal trends in age-standardized rates were assessed using log-linear regression. The Kitagawa-Das Gupta decomposition partitioned the change in estimated deaths into population growth, age-structure change, and age-specific mortality-rate changes. Results: Estimated prevalent cases increased from 48,689 (95% UI, 42,588−56,140) in 1990–90,498 (78,126−105,815) in 2023. Estimated deaths increased from 408 (288−579) to 635 (438−862), while the estimated age-standardized mortality rate declined from 10.2 to 7.9 per 100,000 (APC, −0.46%; 95% CI, −0.64 to −0.29). Decomposition attributed 159.6% of the net increase in deaths to population growth, −7.8% to age-structure change, and −51.8% to lower modeled age-specific rates. In 2023, an estimated 49.5% of deaths occurred before age 20. Point estimates suggested possible higher male mortality, but uncertainty intervals were wide and compatible with no clear sex difference. Conclusions: GBD estimates suggest that Sierra Leone’s absolute burden of sickle cell disorders increased substantially between 1990 and 2023, while modeled rates declined. These modeled estimates highlight a growing absolute burden and persistent early-life mortality, supporting the need for improved surveillance, newborn screening, infection prophylaxis, hydroxyurea access, and longitudinal care systems.

  • Open Access

    Health-system barriers and missed opportunities in cardiovascular care in Sierra Leone: a scoping review

    by Mohamed B. Jalloh, Fatima Jalloh, Mamadu Baldeh, Thiess Lorenz, Foray M. Foray, Tahir Bockarie, Gari D. Clifford, Abdul Jalloh, Andrew Farlow, Bamba Gaye

    Cardiovascular disease (CVD) mortality is rising in Sierra Leone, but the health-system drivers of this trend are not well characterised. We mapped health-system barriers and facilitators for CVD care in Sierra Leone using a systems lens tied to universal health coverage (UHC). We conducted a scoping review following PRISMA-ScR guidelines. We searched MEDLINE, Embase, Scopus, Global Health, and African Journals Online (1 Jan 2000 - 10 May 2025), Of 498 unique records, we included 40 sources reporting CVD-relevant data. Findings were mapped to WHO health-system building blocks, and synthesised narratively. Our findings show a health system shaped by path dependence: investments in infectious disease programmes have strengthened vertical delivery platforms with limited integration of non-communicable disease services. Facility readiness averaged 41% for HIV services versus 16.8% for cardiovascular care. An urban risk paradox was identified: urbanisation increased the odds of hypertension (OR 1.46) and diabetes (OR 1.84), while primary care infrastructure remained more oriented toward rural maternal health. Service delivery was undermined by diagnostic gaps; limited access to neuroimaging for stroke was associated with a threefold increase in mortality. High out-of-pocket costs narrowed effective coverage toward wealthier groups, and recurrent medicine stockouts reinforced distrust and disengagement from formal care. Scalable enablers included task-sharing, digital tools, pooled procurement, and community engagement. Strengthening task-shared primary care, ring-fenced CVD budgets, pooling drug procurement, and improving digital infrastructure could accelerate UHC-effective coverage in Sierra Leone. Evidence on cost-effectiveness and socio-cultural determinants remains limited and should guide implementation research.

  • Open Access

    African Representation in Randomized Controlled Trials Published in Leading Medical and Cardiovascular Journals, 2019-2024

    by Bamba Gaye, Moustafa I. Morsy, David Lagoro Kitara, Gurbinder Singh, Mohsen Shoaran, Danila Gurgone, Daouda Seck, Ahmad Alsaeed, Modou Jobe, Jennifer Carter, et al.


  • Open Access

    Predictors of in-hospital mortality among adults with chronic kidney disease at a national tertiary hospital in Sierra Leone

    by Foray Mohamed Foray, Henry Sankoh, Joshua Coker, John Abdul Koroma, Norman M. Farama-Bangura, Fatima Jalloh, Mark I. Kapuwa, Alhassan Sumah, Soccoh Kabia, Gibrilla Fadlu Deen, et al.

    In-hospital outcomes among adults with chronic kidney disease (CKD) in low-resource settings are poorly characterized. We evaluated predictors of in-hospital mortality among adults admitted with CKD to Sierra Leone's national tertiary hospital, which houses the country's only public dialysis unit. We retrospectively reviewed case notes for all adults with CKD admitted to Connaught Hospital, Freetown, from January 1, 2022, through December 31, 2024. CKD stage was assigned according to KDIGO estimated glomerular filtration rate (eGFR) categories. The primary outcome was in-hospital death. Multivariable logistic regression was used to examine prespecified predictors of mortality. Among 385 admissions (median age, 48 years [interquartile range, 38 to 57]; 57.1% men), 64.2% presented with KDIGO G5 CKD and 41.0% received dialysis. In-hospital death occurred in 95 patients (24.7%). Each 10 mL/min/1.73 m² lower eGFR was associated with higher odds of death (adjusted odds ratio [aOR], 1.94; 95% confidence interval [CI], 1.42 to 2.66), as were heavier proteinuria (aOR, 2.23; 95% CI, 1.39 to 3.58 per one-category increase on dipstick) and diabetes (aOR, 1.97; 95% CI, 1.10 to 3.52). Receipt of dialysis was associated with lower adjusted odds of death (aOR, 0.55; 95% CI, 0.31 to 0.95). Age, sex, and hypertension were not statistically significant. Hospitalized adults with CKD in Sierra Leone typically present with advanced disease and heavy proteinuria, and approximately one in four died during hospitalization. Lower eGFR, greater proteinuria, and diabetes identify patients at highest risk, and access to dialysis was associated with lower short-term survival in this low-resource setting.